Clinical Trials Browser

Multiple Myeloma

Multiple Myeloma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasms

Multiple Myeloma, Neoplasms

Multiple Myeloma

Waldenstrom Macroglobulinemia

Multiple Myeloma

Multiple Myeloma

Hematologic Neoplasms

Multiple Myeloma

Multiple Myeloma, Recurrence

Multiple Myeloma

Multiple Myeloma

Immunoglobulin Light-chain Amyloidosis

Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Renal Insufficiency

Neurofibromatosis 1, Central Nervous System Neoplasms, Optic Nerve Glioma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Multiple Myeloma

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma

Disease, Multiple Myeloma, Recurrence, Disease Progression

Multiple Myeloma

Multiple Myeloma

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Waldenstrom Macroglobulinemia

Amyloidosis, Neoplasms, Plasma Cell

Recurrence, Neoplasms, Plasma Cell

Unspecified Adult Solid Tumor, Protocol Specific

Clinical Trials

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

MajesTEC-2

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

MonumenTAL-2

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

iinnovate-2

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

CAMMA 1

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

CPD-DARA

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

POM Renal

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

PomdeSAR

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

MUKeleven

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

A Pilot Bioequivalence Study of Pomalidomide

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment